期刊
SKELETAL BIOLOGY AND MEDICINE II: BONE AND CARTILAGE HOMEOSTASIS AND BONE DISEASE
卷 1240, 期 -, 页码 18-25出版社
BLACKWELL SCIENCE PUBL
DOI: 10.1111/j.1749-6632.2011.06286.x
关键词
osteoclastogenesis; HDAC inhibitors; trichostatin A; C/EBP-beta; MKP-1
资金
- [NIH-K01-AG034233-02]
- NATIONAL INSTITUTE ON AGING [K01AG034233] Funding Source: NIH RePORTER
Histone deacetylases (HDACs) remove the acetyl groups from the lysine residues of histone tails, leading to the formation of a condensed and transcriptionally silenced chromatin. HDAC inhibitors (HDACi) block this action and can result in hyperacetylation of histones, leading to a less compact and more transcriptionally active chromatin and thereby, gene expression. Previously, we have shown that HDACi inhibit osteoclast differentiation. However, which genes are transcriptionally activated following hyperacetylation of histones, and lead to the suppression of osteoclastogenesis, has yet to be elucidated. In this study, we show that an HDACi, trichostatin A (TSA), inhibits the receptor activator of the nuclear factor-kappa B (NF-kappa B) ligand (RANKL)-stimulated TNF-alpha production, NF-kappa B activation, and bone resorbing pit formation, and downregulates c-Fos and NFATc1 in RAW 264.7 cells. Interestingly, expression of antiosteoclastogenic factors CCAAT enhancer binding protein (C/EBP)-beta and mitogen-activated protein kinase phosphatase (MKP)-1 was significantly upregulated in TSA-treated, RANKL-stimulated RAW 264.7 cells. These findings suggest that TSA upregulates the expression of C/EBP-beta and MKP-1, which may downregulate pro-osteoclastogenic factors and signaling molecules, ultimately suppressing osteoclastogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据